Javascript must be enabled to continue!
Pharmacoinformatics-based investigation of phytochemicals against HIV-1 Reverse Transcriptase
View through CrossRef
Abstract
Purpose
The goal of this study was to examine some anti-HIV phytochemicals that were found in the database and determine how they work. Because some phytochemicals can inhibit more than one target, two reverse transcriptases with PDB IDs 1REV and 1RT1 were used.
Methods
The Dr. Duke Phytochemical and Ethnobotanical Database was used to obtain phytochemicals. ADMET lab 2.0 is used to study in-silico analysis of druglike characteristics and toxicity, to study molecular docking, PyRx virtual screening software, and Biovia Discovery Studio were employed. SiBioLead is an online tool that was used to study molecular dynamics simulation.
Result
23 Phytochemicals with anti-HIV activity were chosen for the current study from Dr. Duke's Phytochemical and Ethnobotanical Databases. Using the ADMET lab2.0 in-silico method, 23 phytochemicals were studied for their druglike properties and toxicity. The six phytochemicals with druglike properties and low toxicity chosen for further research were Chlorogenic acid, Colchicine, Curcumin, Ellagic acid, Myricetin, and Papaverine. These six phytochemicals were docked with two HIV-1 reverse transcriptase proteins with PDB ID: 1REV and 1RT1, using PyRx, and the docking results were analyzed using Biovia Discovery Studio. The docking results of these six phytochemicals were compared to FDA-approved drugs Zidovudine and Nevirapine and found to have better anti-HIV activity. All six phytochemicals had stable interactions with HIV proteins when studied using the online molecular dynamics simulation tool SiBioLead.
Conclusion
According to the findings, the above six chemicals could be promising lead molecules for the treatment of HIV infection.
Title: Pharmacoinformatics-based investigation of phytochemicals against HIV-1 Reverse Transcriptase
Description:
Abstract
Purpose
The goal of this study was to examine some anti-HIV phytochemicals that were found in the database and determine how they work.
Because some phytochemicals can inhibit more than one target, two reverse transcriptases with PDB IDs 1REV and 1RT1 were used.
Methods
The Dr.
Duke Phytochemical and Ethnobotanical Database was used to obtain phytochemicals.
ADMET lab 2.
0 is used to study in-silico analysis of druglike characteristics and toxicity, to study molecular docking, PyRx virtual screening software, and Biovia Discovery Studio were employed.
SiBioLead is an online tool that was used to study molecular dynamics simulation.
Result
23 Phytochemicals with anti-HIV activity were chosen for the current study from Dr.
Duke's Phytochemical and Ethnobotanical Databases.
Using the ADMET lab2.
0 in-silico method, 23 phytochemicals were studied for their druglike properties and toxicity.
The six phytochemicals with druglike properties and low toxicity chosen for further research were Chlorogenic acid, Colchicine, Curcumin, Ellagic acid, Myricetin, and Papaverine.
These six phytochemicals were docked with two HIV-1 reverse transcriptase proteins with PDB ID: 1REV and 1RT1, using PyRx, and the docking results were analyzed using Biovia Discovery Studio.
The docking results of these six phytochemicals were compared to FDA-approved drugs Zidovudine and Nevirapine and found to have better anti-HIV activity.
All six phytochemicals had stable interactions with HIV proteins when studied using the online molecular dynamics simulation tool SiBioLead.
Conclusion
According to the findings, the above six chemicals could be promising lead molecules for the treatment of HIV infection.
Related Results
HIV WGS - 400bp Amplicon Tiling - Oxford Nanopore Technology Protocol v1
HIV WGS - 400bp Amplicon Tiling - Oxford Nanopore Technology Protocol v1
OSPHL in collaboration with APHL, will evaluate the performance of the Oxford Nanopore Technology sequencers for HIV genome sequencing using a modified protocol of the ARTIC amplic...
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
The Hidden Problem of Cross-Reactivity: Challenges in HIV Testing During the COVID-19 Era: A Systematic Review
Abstract
Introduction
Human immunodeficiency virus (HIV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) surface glycoproteins, including shared epitope motifs, sho...
Capítulo 6 – HIV-AIDS, como tratar, o que fazer e o que não fazer durante o tratamento?
Capítulo 6 – HIV-AIDS, como tratar, o que fazer e o que não fazer durante o tratamento?
A infecção pelo vírus do HIV pode ocorrer de diversas maneiras, tendo sua principal forma a via sexual por meio do sexo desprotegido. O vírus do HIV fica em um período de incubação...
In-vitro Study of HIV-derived Reverse Transcriptase Inhibition
In-vitro Study of HIV-derived Reverse Transcriptase Inhibition
Introduction:
HIV utilizes a reverse transcriptase (RT) enzyme to convert the HIVRNA
into DNA. Inhibition of the reverse transcription mechanism of HIV-RT may serve as a
potential ...
Laboratory-based Evaluation of Wondfo HIV1/2 Rapid Test Kits in the Gambia, December 2020
Laboratory-based Evaluation of Wondfo HIV1/2 Rapid Test Kits in the Gambia, December 2020
Background: HIV rapid diagnosis in The Gambia is mainly done using Determine HIV-1/2 and First Response HIV 1.2.0 or SD Bioline HIV-1/2 3.0 for screening and sero-typing of HIV res...
Impact of HIV/AIDS scale-up on non-HIV priority services in Nyanza Province, Kenya
Impact of HIV/AIDS scale-up on non-HIV priority services in Nyanza Province, Kenya
Background: The HIV pandemic has attracted unprecedented scale-up in resources to curb its escalation and manage those afflicted. Although evidence from developing countries sugges...
Evaluasi peningkatan pengetahuan tentang HIV/AIDS dan sikap terhadap ODHA di SMK Gelora Jaya Nusantara
Evaluasi peningkatan pengetahuan tentang HIV/AIDS dan sikap terhadap ODHA di SMK Gelora Jaya Nusantara
Background: HIV/AIDS remains a global health problem in Indonesia, with major barriers being misunderstandings, social stigma, and ineffective educational approaches. The level of ...
Abstract 5594: Progression of paraproteinemia in HIV-positive versus HIV-negative patients
Abstract 5594: Progression of paraproteinemia in HIV-positive versus HIV-negative patients
Abstract
BACKGROUND: Paraproteinemias occur in 1 to 3% of people over the age of 50 and progress to hematological malignancies (HM) at the rate of about 1% per year....

